San Francisco, California (March 16, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2020 and provided updates on its programs. For the fourth quarter of 2020, KindredBio reported net revenues […]
Tuesday, March 16, 2021 Time of Event: 4:30 p.m. Eastern time/1:30 p.m. Pacific time Telephone Dial in: toll-free (855) 433-0927 from the U.S. or (484) 756-4262 internationally Conference ID: 3989605 For more information about this event, please see the press release.
Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on Tuesday, March 16, 2021. San Francisco, California (March 8, 2021) — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its fourth quarter and full year 2020 financial results […]
March 9-10 Presentation time: On demand presentation Company Attendee: CEO Richard Chin For more information about this event, please see the press release.
Wednesday, March 10 Presentation time: 2:25p.m. ET Company Attendee: CEO Richard Chin For more information about this event, please see the press release.
SAN FRANCISCO, March 2, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the Barclays Global Healthcare Conference on March 10 and the H.C. Wainwright Global Life Sciences Conference on March 9-10. Dr. Richard Chin, Chief Executive Officer, will be available for one-on-one meetings. […]
San Francisco, California (February 25, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has submitted efficacy data to support the prophylactic indication for KIND-030 to the United States Department of Agriculture (USDA) Center for Veterinary Biologics for review. This submission […]
Thursday, February 25 Presentation time: 10:50a.m. ET Company Attendee: CEO Richard Chin For more information about this event, please see the press release.
SAN FRANCISCO, February 16, 2021 — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will present at the BofA Securities Animal Health Virtual Summit on February 25. Dr. Richard Chin, Chief Executive Officer, will present via webcast at 10.50am ET and be available for virtual one-on-one meetings. During this […]
San Francisco, California (February 9, 2021) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has appointed Lyndon Lien, Ph.D., an experienced biotech CEO, entrepreneur and investor, and Nanxi Liu, CEO and Co-Founder of Enplug and Co-Founder of Nanoly Bioscience, to its […]
0.10 (1.99%)
|
||||||||||||||||